title: Possibilities of preventing osteoradionecrosis during complex therapy of tumors of the oral cavity.
abstract: In recent years, there has been a dramatic increase in the number of tumors of the head and neck. Their successful treatment is one of the greatest challenges for physicians dealing with oncotherapy. An organic part of the complex therapy is preoperative or postoperative irradiation. Application of this is accompanied by a lower risk of recurrences, and by a higher proportion of cured patients. Unfortunately, irradiation also has a disadvantage: the development of osteoradionecrosis, a special form of osteomyelitis, in some patients (mainly in those cases where irradiation occurs after bone resection or after partial removal of the periosteum). Once the clinical picture of this irradiation complication has developed, its treatment is very difficult. A significant result or complete freedom from complaints can be attained only rarely. Attention must therefore be focussed primarily on prevention, and the oral surgeon, the oncoradiologist and the patient too can all do much to help prevent the occurrence of osteoradionecrosis. Through coupling of an up-to-date, functional surgical attitude with knowledge relating to modern radiology and radiation physics, the way may be opened to forestall this complication that is so difficult to cure.
authors.affiliation: Semmelweis University, Department of Oral and Maxillofacial Surgery Mária u. 52., Budapest, H-1085, Hungary.
authors.forename: Z
authors.initials: Z
authors.lastname: Németh
authors.forename: A
authors.initials: A
authors.lastname: Somogyi
authors.forename: Z
authors.initials: Z
authors.lastname: Takácsi-Nagy
authors.forename: J
authors.initials: J
authors.lastname: Barabás
authors.forename: G
authors.initials: G
authors.lastname: Németh
authors.forename: G
authors.initials: G
authors.lastname: Szabó
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D017577:Cutaneous Fistula / Q000209:etiology; D005402:Fistula / Q000209:etiology; D006801:Humans; D007568:Jaw / Q000000981:diagnostic imaging / Q000473:pathology / Q000528:radiation effects; D007571:Jaw Diseases / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D008936:Mitolactol / Q000008:administration & dosage; D009062:Mouth Neoplasms / Q000532:radiotherapy*; D009910:Oral Hygiene; D056948:Orthognathic Surgical Procedures; D010025:Osteoradionecrosis / Q000517:prevention & control*; D010027:Osteotomy; D011183:Postoperative Complications; D011292:Premedication; D011867:Radioisotope Teletherapy / Q000009:adverse effects / Q000379:methods; D011878:Radiotherapy / Q000009:adverse effects*; D012542:Scattering, Radiation; D013518:Surgery, Plastic; D013524:Surgical Flaps; D014057:Tomography, X-Ray Computed; D014062:Tongue Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D014076:Tooth Diseases / Q000209:etiology / Q000517:prevention & control*; D014081:Tooth Extraction; D014750:Vincristine / Q000008:administration & dosage; D014945:Wound Healing
chemical_list: D018906:Antineoplastic Agents, Alkylating; D001761:Bleomycin; D014750:Vincristine; D008936:Mitolactol; D002945:Cisplatin; D008727:Methotrexate